Concord Biotech Limited Capital Reinvestment Ratio
Concord Biotech Limited capital reinvestment ratio. Concord Biotech Limited (CONCORDBIO) has a Capital Reinvestment Ratio of 0.45x as of March 2025, meaning it reinvests 0% of its operating cash flow (Rs2.47 Billion) in capital expenditures (Rs1.11 Billion). Check Concord Biotech Limited total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Concord Biotech Limited (2020–2025)
Capital reinvestment ratio of Concord Biotech Limited from 2020 to 2025. This chart tracks Concord Biotech Limited's Capital Reinvestment Ratio across 6 annual periods. Also explore Concord Biotech Limited net asset momentum to track the company's year-over-year net asset growth rate.
Concord Biotech Limited Capital Reinvestment Ratio by Year (2020–2025)
Concord Biotech Limited capital reinvestment ratio by year from 2020 to 2025. For the full cash flow conversion analysis, see Concord Biotech Limited (CONCORDBIO) cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (INR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.45x | Rs2.47 Billion | Rs1.11 Billion | ▲ +39.2% |
| 2024 | 0.32x | Rs2.65 Billion | Rs856.88 Million | ▼ -45.3% |
| 2023 | 0.59x | Rs2.46 Billion | Rs1.45 Billion | ▼ -21.3% |
| 2022 | 0.75x | Rs2.07 Billion | Rs1.56 Billion | ▼ -38.8% |
| 2021 | 1.22x | Rs1.67 Billion | Rs2.04 Billion | ▲ +21.9% |
| 2020 | 1.00x | Rs1.55 Billion | Rs1.55 Billion | — |